Abstract | AIM: METHODS: A randomized controlled double-blind and double-dummy multicentre clinical trial was conducted. A total of 230 Chinese patients with type 2 diabetes were enrolled in five clinical centres. The patients were divided randomly into group A [ repaglinide 1.0 mg three times daily (t.i.d.), n = 115] or group B ( nateglinide 90 mg t.i.d., n = 115). At baseline and end of the 12-week clinical trial, standard mixed meal tolerance tests were performed. RESULTS: A total of 223 patients (96.9%) completed the trial. There was no significant difference between repaglinide and nateglinide groups in the effects of reducing fasting blood glucose (FBG), 30-, 60- and 120-min BG during 12 weeks (p > 0.05). At week 12, no significant difference was shown between the two groups in BG or haemoglobin A(1c) (HbA(1c)) (p > 0.05). However, the effect on HbA(1c) in repaglinide group was stronger than that in nateglinide group (p < 0.05). After 12-week treatment, area under the curve (AUC) of BG decreased (p < 0.05), and AUC of insulin and C-peptide (CP) increased in both groups (p < 0.05). The effects of nateglinide on AUC of BG, insulin and CP were similar to that of repaglinide (p > 0.05). There was no significant difference between the two groups in AUC of BG, insulin or CP in week 12 (p > 0.05). Furthermore, homeostasis model assessment of insulin resistance (HOMA-IR) and beta-cell function indexes measured by HOMA-beta, DeltaI(30)/DeltaG(30) and (DeltaI(30)/DeltaG(30))/HOMA-IR were improved significantly in both groups during 12 weeks (p < 0.05). The effects of improving HOMA-IR and beta-cell function indexes in nateglinide group were comparable with that of repaglinide group (p > 0.05). CONCLUSIONS:
|
Authors | J Li, H Tian, Q Li, N Wang, T Wu, Y Liu, Z Ni, H Yu, J Liang, R Luo, Y Li, L Huang |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 9
Issue 4
Pg. 558-65
(Jul 2007)
ISSN: 1462-8902 [Print] England |
PMID | 17587398
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Blood Glucose
- Carbamates
- Cyclohexanes
- Insulin
- Piperidines
- Nateglinide
- Phenylalanine
- repaglinide
|
Topics |
- Adult
- Age of Onset
- Aged
- Area Under Curve
- Asian People
- Blood Glucose
(metabolism)
- Carbamates
(therapeutic use)
- China
- Cyclohexanes
(therapeutic use)
- Diabetes Mellitus, Type 2
(drug therapy)
- Double-Blind Method
- Humans
- Insulin
(blood, metabolism)
- Insulin Secretion
- Insulin-Secreting Cells
(drug effects, metabolism, physiology)
- Middle Aged
- Nateglinide
- Phenylalanine
(analogs & derivatives, therapeutic use)
- Piperidines
(therapeutic use)
|